B. Metzler seel. Sohn & Co. AG Increases Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

B. Metzler seel. Sohn & Co. AG raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 255.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,618 shares of the medical equipment provider’s stock after purchasing an additional 14,093 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Zimmer Biomet were worth $1,932,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Rakuten Investment Management Inc. purchased a new position in Zimmer Biomet in the third quarter worth $37,307,000. Sector Gamma AS raised its position in Zimmer Biomet by 28.0% during the third quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider’s stock valued at $11,178,000 after purchasing an additional 24,847 shares in the last quarter. SG Americas Securities LLC raised its position in Zimmer Biomet by 29.2% during the third quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider’s stock valued at $6,019,000 after purchasing an additional 13,812 shares in the last quarter. Border to Coast Pensions Partnership Ltd lifted its stake in Zimmer Biomet by 6.5% during the third quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock worth $35,506,000 after purchasing an additional 22,104 shares during the last quarter. Finally, National Pension Service lifted its stake in Zimmer Biomet by 4.5% during the third quarter. National Pension Service now owns 393,476 shares of the medical equipment provider’s stock worth $38,757,000 after purchasing an additional 16,928 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. BTIG Research reiterated a “buy” rating and set a $112.00 price objective on shares of Zimmer Biomet in a research report on Tuesday, February 10th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, February 10th. Wall Street Zen lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their price target for the stock from $94.00 to $120.00 in a research note on Monday, January 5th. Finally, The Goldman Sachs Group lowered shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective for the company. in a report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average target price of $106.20.

Zimmer Biomet Trading Down 1.6%

Shares of ZBH stock opened at $91.78 on Wednesday. The business has a 50-day moving average of $92.21 and a 200 day moving average of $95.41. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. Zimmer Biomet Holdings, Inc. has a 1-year low of $84.59 and a 1-year high of $114.44. The stock has a market capitalization of $17.96 billion, a PE ratio of 25.93, a P/E/G ratio of 1.91 and a beta of 0.58.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The business had revenue of $2.24 billion for the quarter, compared to analysts’ expectations of $2.22 billion. During the same period in the previous year, the firm earned $2.31 EPS. The business’s quarterly revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s payout ratio is presently 27.12%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.